BRIEF-SpringWorks Therapeutics to Present Phase 3 DeFi Trial Data of Ogsiveo in Desmoid Tumors at CTOS 2024 Meeting

Reuters
07 Nov 2024

Nov 7 (Reuters) - SpringWorks Therapeutics Inc :

* SPRINGWORKS THERAPEUTICS ANNOUNCES LONG-TERM EFFICACY AND SAFETY DATA FROM PHASE 3 DEFI TRIAL OF OGSIVEO® (NIROGACESTAT) IN ADULTS WITH DESMOID TUMORS TO BE PRESENTED AT THE CONNECTIVE TISSUE ONCOLOGY SOCIETY $(CTOS)$ 2024 ANNUAL MEETING

* SPRINGWORKS THERAPEUTICS INC - NIROGACESTAT SHOWS FURTHER TUMOR SIZE REDUCTIONS AND INCREASED ORR

* SPRINGWORKS THERAPEUTICS INC - MEDIAN TUMOR SIZE REDUCTION OF −75.8% AFTER FOUR YEARS OF NIROGACESTAT

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10